229 related articles for article (PubMed ID: 33231796)
1. Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors.
Kushlinskii NE; Alferov AA; Timofeev YS; Gershtein ES; Bulycheva IV; Bondarev AV; Shchupak MY; Sokolov NY; Polikarpova SB; Efimova MM; Dzampaev AA; Sushentsov EA; Aliev MD; Musaev ER
Bull Exp Biol Med; 2020 Nov; 170(1):64-68. PubMed ID: 33231796
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
[TBL] [Abstract][Full Text] [Related]
3. Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors.
Kushlinskii NE; Timofeev YS; Solov'ev YN; Gerstein ES; Lyubimova NV; Bulycheva IV
Bull Exp Biol Med; 2014 Aug; 157(4):520-3. PubMed ID: 25110097
[TBL] [Abstract][Full Text] [Related]
4. Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma.
Trieb K; Gerth R; Windhager R; Grohs JG; Holzer G; Berger P; Kotz R
Immunobiology; 2000 Jan; 201(3-4):368-76. PubMed ID: 10776793
[TBL] [Abstract][Full Text] [Related]
5. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
6. Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
[TBL] [Abstract][Full Text] [Related]
7. sCD30 and sCD40L detection in patients with osteosarcoma, chondrosarcoma and Ewing sarcoma.
Solooki S; Khozaei A; Shamsdin SA; Emami MJ; Khademolhosseini F
Iran J Immunol; 2013 Dec; 10(4):229-37. PubMed ID: 24375064
[TBL] [Abstract][Full Text] [Related]
8. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
9. New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract][Full Text] [Related]
10. What's new in primary bone tumors.
Schwab JH; Springfield DS; Raskin KA; Mankin HJ; Hornicek FJ
J Bone Joint Surg Am; 2012 Oct; 94(20):1913-9. PubMed ID: 23079883
[No Abstract] [Full Text] [Related]
11. Primary malignant bone tumors--recent developments.
Hameed M; Dorfman H
Semin Diagn Pathol; 2011 Feb; 28(1):86-101. PubMed ID: 21675380
[TBL] [Abstract][Full Text] [Related]
12. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
13. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
14. [Cytogenetic and molecular genetic changes in malignant primary bone tumors].
Zoubek A; Kovar H; Gadner H
Radiologe; 1998 Jun; 38(6):467-71. PubMed ID: 9700767
[TBL] [Abstract][Full Text] [Related]
15. Association of extent of local tumor invasion and survival in patients with malignant primary osseous spinal neoplasms from the surveillance, epidemiology, and end results (SEER) database.
Mukherjee D; Chaichana KL; Adogwa O; Gokaslan Z; Aaronson O; Cheng JS; McGirt MJ
World Neurosurg; 2011 Dec; 76(6):580-5. PubMed ID: 22251507
[TBL] [Abstract][Full Text] [Related]
16. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
17. What's new in primary bone tumors.
Schwab JH; Lozano-Calderon SA; Mankin HJ; Raskin KA; Hornicek FJ
J Bone Joint Surg Am; 2014 Dec; 96(24):2099-104. PubMed ID: 25520345
[No Abstract] [Full Text] [Related]
18. microRNA and Bone Cancer.
Nugent M
Adv Exp Med Biol; 2015; 889():201-30. PubMed ID: 26659003
[TBL] [Abstract][Full Text] [Related]
19. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
[TBL] [Abstract][Full Text] [Related]
20. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
